The Interplay Between FDA Approval And Discovery Rule

Law360, New York (March 8, 2012, 1:26 PM EST) -- Adopting a middle-of-the-road approach that may raise more questions than it answers, the New Jersey Supreme Court has ruled that U.S. Food and Drug Administration (FDA) approval of drug and medical device warnings creates a presumption against application of the discovery rule to a defendant’s otherwise-valid statute of limitations defense.

New Jersey’s Product Liability Act (PLA) creates a rebuttable presumption that warnings or instructions approved by the FDA are adequate. Indeed, in discussing the impact of this presumption on the merits of a plaintiff’s failure-to-warn claim,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.